Metabolic reprogramming of myeloid-derived suppressor cells (MDSC) in cancer

Amir A Al-Khami; Paulo C Rodriguez; Augusto C Ochoa

doi:10.1080/2162402X.2016.1200771

Metabolic reprogramming of myeloid-derived suppressor cells (MDSC) in cancer

Oncoimmunology. 2016 Jun 27;5(8):e1200771. doi: 10.1080/2162402X.2016.1200771. eCollection 2016 Aug.

Authors

Amir A Al-Khami¹, Paulo C Rodriguez², Augusto C Ochoa³

Affiliations

¹ Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA; Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
² Georgia Regents University Cancer Center , Augusta, GA, USA.
³ Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA; Department of Pediatrics, Louisiana State University Health Sciences Center, New Orleans, LA, USA.

Abstract

MDSC undergo metabolic reprogramming in the tumor resulting in an increased fatty acid β oxidation that supports their immunosuppressive functions. Fatty acid oxidation inhibitors, used to treat coronary disease, significantly delayed tumor growth and had a significantly increased antitumor effect when combined with adoptive cell therapy or low dose chemotherapy.

Keywords: Cancer; Immunometabolism; MDSC.

Publication types

Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

Abstract

Publication types

Grants and funding